- Home
- MEIP vs XHG Comparison
MEIP vs XHG Comparison
Compare MEIP & XHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- XHG
- Stock Information
- Founded
- MEIP 2000
- XHG 2012
- Country
- MEIP United States
- XHG China
- Employees
- MEIP N/A
- XHG N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- XHG
- Sector
- MEIP Health Care
- XHG
- Exchange
- MEIP Nasdaq
- XHG NYSE
- Market Cap
- MEIP 16.3M
- XHG 15.0M
- IPO Year
- MEIP 2003
- XHG 2019
- Fundamental
- Price
- MEIP $2.87
- XHG $1.14
- Analyst Decision
- MEIP Hold
- XHG
- Analyst Count
- MEIP 2
- XHG 0
- Target Price
- MEIP $7.00
- XHG N/A
- AVG Volume (30 Days)
- MEIP 36.2K
- XHG 12.4M
- Earning Date
- MEIP 02-11-2025
- XHG 01-24-2025
- Dividend Yield
- MEIP N/A
- XHG N/A
- EPS Growth
- MEIP N/A
- XHG N/A
- EPS
- MEIP N/A
- XHG 210.47
- Revenue
- MEIP N/A
- XHG $10,628,627.00
- Revenue This Year
- MEIP N/A
- XHG N/A
- Revenue Next Year
- MEIP $300.00
- XHG N/A
- P/E Ratio
- MEIP N/A
- XHG $0.15
- Revenue Growth
- MEIP 33.76
- XHG N/A
- 52 Week Low
- MEIP $2.30
- XHG $0.64
- 52 Week High
- MEIP $4.97
- XHG $60.00
- Technical
- Relative Strength Index (RSI)
- MEIP 66.22
- XHG 47.46
- Support Level
- MEIP $2.56
- XHG $0.90
- Resistance Level
- MEIP $2.78
- XHG $3.08
- Average True Range (ATR)
- MEIP 0.15
- XHG 0.39
- MACD
- MEIP 0.04
- XHG 0.08
- Stochastic Oscillator
- MEIP 100.00
- XHG 16.60
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About XHG XCHANGE TEC.INC SPON ADS EACH REP 600000 SHS(POST SPLIT)
XChange Tec Inc, through its subsidiaries operates in insurance agency and insurance technology business. Its insurance products include industry and/or state-owned property and casualty insurance and regional property and casualty insurance. The insurance technology business is focused on operating and developing insurance technology in the PRC, including developing SaaS platform to connect consumers and underwriting support.